Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Pharm-country    symbols : Legn    save search

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 0.02% H: 0.22% C: -0.88%

first conference biotech results
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Published: 2024-03-19 (Crawled : 14:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -1.56% H: 0.99% C: -1.3%

report biotech publication
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M twitter stocktwits trandingview |
Health Technology
| | O: -1.58% H: 0.0% C: 0.0%
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -0.27% H: 4.91% C: -2.9%

carvykti fda treatment
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M twitter stocktwits trandingview |
Health Technology
| | O: 0.28% H: 0.0% C: 0.0%
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 2.07% H: 5.02% C: 4.92%

carvykti chmp biotech positive treatment therapy
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -1.18% H: 2.49% C: -0.61%

conference biotech
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 0.78% H: 3.23% C: 2.76%

carvykti life treatment study
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
Published: 2023-08-15 (Crawled : 11:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -8.81% H: 7.25% C: 4.36%

biotech results
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
Published: 2023-05-08 (Crawled : 13:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -2.42% H: 5.43% C: 5.16%

biotech corporation direct offering
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.44% C: -2.11%

lb2102 fda clearance lung biotech application cancer
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -0.21% H: 1.61% C: 0.23%

day biotech
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
Published: 2022-08-05 (Crawled : 13:20) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 0.44% H: 0.5% C: -0.78%

biotech
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
Published: 2022-05-18 (Crawled : 14:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -2.15% H: 2.71% C: -0.76%

treatment biotech car-t asco
Legend Biotech Announces Appointment of Global Head of Research and Early Development
Published: 2022-04-01 (Crawled : 21:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 3.52% H: 5.24% C: 3.93%

research biotech
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
Published: 2022-02-18 (Crawled : 14:30) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 2.65% C: -1.66%

ces results biotech iot
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
Published: 2021-12-30 (Crawled : 16:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -0.3% H: 5.62% C: 5.58%

biotech iot
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-07 (Crawled : 14:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -0.09% H: 9.78% C: 8.43%

ema biotech iot
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 2.7% H: 0.0% C: 0.0%

new drug treatment application car-t drug therapy biotech iot submission cel
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: -0.37% H: 0.8% C: 0.33%

treatment europe therapy car-t biotech iot submission cel
Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
Published: 2020-12-14 (Crawled : 16:00) - biospace.com/
LEGN | $46.36 -1.61% 510K twitter stocktwits trandingview |
Health Technology
| | O: 2.1% H: 9.14% C: 4.64%

fda fda clearance biotech therapy car-t t-cell clearance
Gainers vs Losers
73% 27%

Top 10 Gainers
AGBA | News | $1.27 217.5% 120M twitter stocktwits trandingview |
Finance

EGOX | $0.054 50.0% 290M twitter stocktwits trandingview |

RWOD | $10.52 31.56% 5.9M twitter stocktwits trandingview |
n/a

ZCMD | $1.905 31.38% 30M twitter stocktwits trandingview |
Commercial Services

NVFY | $2.71 28.44% 31M twitter stocktwits trandingview |
Consumer Durables

MRDB 4 | $0.536 27.65% 2M twitter stocktwits trandingview |
n/a

BSFC | $0.0822 27.64% 75M twitter stocktwits trandingview |
Manufacturing

INDO | $5.1 25.0% 15M twitter stocktwits trandingview |
Energy Minerals

CHRO | $1.53 24.9% 100K twitter stocktwits trandingview |
n/a

AULT | $0.2998 23.83% 53M twitter stocktwits trandingview |
Manufacturing


Your saved searches
Save your searches and get alerts when important news are released.